Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'

Research output: Contribution to journalArticle

Abstract

The AIRE gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with AIRE-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with AIRE-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.

Details

Authors
  • Nils Landegren
  • Lindsey B. Rosen
  • Eva Freyhult
  • Daniel Eriksson
  • Tove Fall
  • Gustav Smith
  • Elise M.N. Ferre
  • Petter Brodin
  • Donald Sharon
  • Michael Snyder
  • Michail Lionakis
  • Mark Anderson
  • Olle Kämpe
Organisations
External organisations
  • Karolinska University Hospital
  • Uppsala University
  • National Institute of Allergy and Infectious Diseases
  • Massachusetts Institute of Technology
  • Karolinska Institutet
  • Stanford University
  • University of Bergen
  • Skåne University Hospital
  • University of California, San Francisco
  • Lund University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
  • Immunology in the medical area

Keywords

  • APS1/APECED, autoantibody, autoantigen, human, human biology, immune tolerance, immunology, inflammation, medicine, type 1 diabetes
Original languageEnglish
JournaleLife
Volume8
Publication statusE-pub ahead of print - 2019 Jun 27
Publication categoryResearch
Peer-reviewedYes